Good phase II results for Janssen
At branches of Johnson & Johnson (NOT A WORD), Janssen, announced positive phase II results for the monoclonal antibody nipocalimab being evaluated in pregnant women at high risk of severe hemolytic disease of the fetus and newborn (HDFN). This serious and rare disease can occur when the blood groups of a pregnant woman and her fetus are incompatible. There are currently no approved treatments for the treatment of HDFN.
US green light for GSK
The FDA has just approved the Jeperli (supplylimab-gxly) de GSK for the treatment of patients with recurrent or advanced mismatch repair deficient endometrial cancer. During its phase III conducted on 141 patients, the overall response rate to the monoclonal antibody was 45.4%. Endometrial cancer is the most common gynecological cancer in the world, with approximately 417,000 new cases reported each year worldwide.
VOS INDICES
source
Ipsen advances on kidney cancer
Ipsen presented the three-year results of the phase III trial of Cabometyx (cabozantinib) in combination with nivolumab, in the first-line treatment of advanced kidney cancer (RCC). In combination, this tyrosine kinase inhibitor increased median overall survival compared to sunitinib, increasing it from 35.5 to 49.5 months. RCC is the most common type of kidney cancer and accounts for regarding 90% of cases.
Selected for you
